Find a clear path forward to

echocardiogram image

enhancements

Echocardiography remains central to the assessment and management of cardiac disease; however, many scans may be suboptimal.^1-3 Did you know that an estimated 10-15% of routine echocardiograms and 25-30% of those performed in the ICU are suboptimal? ^2,3

This can affect patient care through:

• Diminished diagnostic accuracy⁴
• Changes in clinical management⁵
• Additional testing⁵

By using an ultrasound enhancing agent (UEA), 75-90% of suboptimal echocardiograms can be made interpretable.⁴

GE HealthCare offers Optison™ (Perflutren Protein-Type A Microspheres Injectable Suspension, USP), the only UEA that does not require a kit or equipment to prepare, and offers the most flexibility to use where and when you need it.

Please scroll to the bottom of this page to see Important Safety Information about Optison, including Boxed Warning.

Easily stored and portable for a simplified workflow, Optison is on the go with you, ready wherever your patients need it. It has a safety profile established over decades of use and is the only FDA approved UEA that does not contain polyethylene glycol (PEG).^6,7

To learn more about how Optison can help improve your workflow, please complete the form on the right to download our infographic.

References

1. Potter A, Pearce K, Hilmy N. The benefits of echocardiography in primary care. BJGP. 2019;69(684):358-359.
2. Senior R, Dwivedi G, Hayat S, Keng Lim T. Clinical benefits of contrast-enhanced echocardiography during rest and stress examinations. Eur J Echocardiogr. 2005;6 Suppl 2:S6-S13.
3. Kurt M, Shaikh KA, Peterson L, et al. Impact of contrast echocardiography on evaluation of ventricular function and clinical management in a large prospective cohort. J Am Coll Cardiol. 2009;53(9):802-810.
4. Mulvagh SL, Rakowski H, Vannan MA, et al. American Society of Echocardiography consensus statement on the clinical applications of ultrasonic contrast agents in echocardiography. J Am Soc Echocardiogr. 2008;21(11):1179-1201
5.  Prentice R, Ahmadian H, Thomas D, Berger J, Gore R. Improved efficiency and diagnostic utility of inpatient transthoracic echocardiography following implementation of a sonographer-initiated perflutren-based contrast administration protocol. Cardiovasc Ultrasound. 2020;18(1):35.
6. FDA Warns Against Some Ultrasound Contrast Agents in Patients with PEG Allergy. American College of Radiology (ACR). https://www.acr.org/Advocacy-and-Economics/Advocacy-News/Advocacy-News-Issues/In-the-April-24-2021-Issue/FDA-Warns-Against-Some-Ultrasound-Contrast-Agents. Published 2022. Accessed January 11, 2023.
7. Lindner JR, Belcik T, Main ML, et al. Expert Consensus Statement from the American Society of Echocardiography on Hypersensitivity Reactions to Ultrasound Enhancing Agents in Patients with Allergy to Polyethylene Glycol (PEG). American Society of Echocardiography. https://www.asecho.org/wp-content/uploads/2021/05/ASE-2526_FDA-EDC-Document_p5.pdf. Published April 2021. Accessed January 11, 2023.

IMPORTANT SAFETY INFORMATION ABOUT OPTISON

WARNING: SERIOUS CARDIOPULMONARY REACTIONS Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following perflutren-containing microsphere administration. Most serious reactions occur within 30 minutes of administration Assess all patients for the presence of any condition that precludes Optison administration Always have resuscitation equipment and trained personnel readily available

INDICATIONS AND USAGE: OPTISON is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricle and to improve the delineation of the left ventricular endocardial borders.

CONTRAINDICATION: Do not administer OPTISON to patients with known or suspected hypersensitivity to perflutren or albumin.

ADVERSE EVENTS: The most frequently reported adverse reactions in clinical trials were headache, nausea and/or vomiting, warm sensation or flushing and dizziness. Cardiac arrests and other serious but nonfatal adverse reactions were uncommonly reported in post-approval use. Reports also identified neurologic reactions (loss of consciousness or convulsions) as well as anaphylactoid reactions.

Please see Full Prescribing Information for Optison here.

Download Now